Metabolic syndrome and breast cancer survivors: a follow-up analysis after completion of chemotherapy.
Metabolic syndrome and breast cancer survivors: a follow-up analysis after completion of chemotherapy.
复制标题
DOI：
10.1186/s13098-022-00807-y
复制
发表时间：
2022-03-03
影响因子：
4.8
通讯作者：
Mortimer JE
中科院分区：
文献类型：
--
作者：
Dieli-Conwright CM;Wong L;Waliany S;Mortimer JE
我们之前报道过，在女性接受 12 至 18 周的化疗疗程后，（新）辅助化疗对代谢综合征 (MetS) 的组成部分、身体成分和相关生物标志物产生了不利的改变。在这里，我们试图确定在同一早期乳腺癌幸存者样本中，这些指标是否会在化疗后 4-5 年内恶化。化疗后 4-5 年内对 28 名乳腺癌幸存者进行了重新评估。在后续体检期间，对参与者进行了 MetS、血脂谱（总胆固醇；TC、低密度脂蛋白胆固醇；LDL-C）、葡萄糖代谢（胰岛素、稳态模型胰岛素抵抗；HOMA-IR、糖化血红蛋白；HbA1c）、炎症（C 反应蛋白；CRP）和身体成分（体重；BW、体脂百分比；BF、脂肪量；FM）测试。使用重复测量协方差分析对化疗后和随访期间的测量结果进行比较。大多数研究患者是白人 (44%) 或西班牙裔 (30%)，平均年龄为 48.2 岁。完成化疗的平均时间为 4.75 年。随访时，与化疗后评估相比，MetS 成分显着增加 (p<0.01)。此外，BF、FM、脂质（TC、LDL）、葡萄糖代谢（HOMA-IR、胰岛素、HbA1c）和炎症（CRP）显着增加（p<0.01）。值得注意的是BW显着增加；化疗后平均体重增加 6.1 公斤，随访时额外增加 8.2% (p<0.01)。乳腺癌幸存者化疗后 4-5 年内，MetS 成分、身体成分和生物标志物持续恶化。能量平衡干预措施应针对乳腺癌患者，以减少 MetS 的恶化。
We previously reported that (neo)adjuvant chemotherapy adversely altered metabolic syndrome (MetS) components, body composition, and related biomarkers after a 12 to 18-week chemotherapy treatment course in women. Here, we sought to determine whether these measures worsened within 4–5 years post-chemotherapy among the same sample of early stage breast cancer survivors. Twenty-eight breast cancer survivors were reassessed within 4–5 years post-chemotherapy. Participants were tested for MetS, lipid profile (total cholesterol; TC, low-density lipoprotein cholesterol; LDL-C), glucose metabolism (insulin, homeostatic model- insulin resistance; HOMA-IR, glycosylated hemoglobin; HbA1c), inflammation (C-reactive protein; CRP) and body composition (body weight; BW, percent body fat; BF, fat mass; FM) during follow-up physical exams. A comparison of measurements between post-chemotherapy and follow-up periods was performed using repeated measures analysis of covariance. Most study patients were Caucasian (44%) or Hispanic (30%) with a mean age of 48.2 years. Average time from completion of chemotherapy was 4.75 years. At follow-up, MetS components significantly increased (p < 0.01) compared with the post chemotherapy assessment. Additionally, BF, FM, lipids (TC, LDL), glucose metabolism (HOMA-IR, insulin, HbA1c), and inflammation (CRP) significantly increased (p < 0.01). Notably BW significantly increased; mean weight gain after chemotherapy was 6.1 kg and increased an additional 8.2% at follow-up (p < 0.01). MetS components, body composition, and biomarkers continued to worsen within 4–5 years post-chemotherapy in breast cancer survivors. Energy balance interventions should target breast cancer patients to reduce the exacerbation of MetS.
登录
查看更多内容
DOI：
10.1016/j.numecd.2009.02.006
发表时间：
2010-01
期刊：
Nutrition, metabolism, and cardiovascular diseases : NMCD
影响因子：
--
作者：
Agnoli C;Berrino F;Abagnato CA;Muti P;Panico S;Crosignani P;Krogh V
通讯作者：
Krogh V
影响因子：
2.4
作者：
Fang, Qiong;Huang, Jiahui;Wu, Beiwen
通讯作者：
Wu, Beiwen
影响因子：
9.5
作者：
Gohlke-Bärwolf, C
通讯作者：
Gohlke-Bärwolf, C
DOI：
10.1161/atvbaha.107.151092
发表时间：
2008-04-01
影响因子：
8.7
作者：
Grundy, Scott M.
通讯作者：
Grundy, Scott M.
影响因子：
3.8
作者：
Courneya, Kerry S.;Sellar, Christopher M.;Reiman, Tony
通讯作者：
Reiman, Tony